Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Among the most research-supported applications is the gastrointestinal system, where BPC-157 has been linked to protection of the gut lining and the stomach against ulceration
However, BPC-157 does not have a universally accepted human dosage, and it is not FDA approved as a standard medication
Familial hypophosphatemia, Fanconi syndrome, hypoparathyroidism, osteomalacia, psoriasis, renal osteodystrophy, rickets, osteoporosis, vitamin D3 deficiency induced falls, cancer prevention, dental caries, hyperparathyroidism-related bone loss, multiple sclerosis, respiratory tract infections, rheumatoid arthritis, tooth retension, weight loss, asthma, cardiovascular disease, chronic kidney disease, improving lung function, Type 2 diabetes, hyperlipidemia, hypertension, overall mortality, myelodysplastic syndrome, periodontal disease, periodontal disease for adults aged 50 and older, reducing PMS symptoms, proximal myopathy, seasonal affective disorder, myalgia, vaginal atrophy, UTI prevention and influenza
Product Overview This precise 1:1 co-lyophilized blend combines a synthetic gastric-derived pentadecapeptide (BPC-157) with an actin-sequestering protein derivative (TB-500 / Thymosin $\beta$4)
